Innovent Biologics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 8,754

Employees

  • Stock Symbol
  • 01801

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $10.80
  • (As of Friday Closing)

Innovent Biologics General Information

Description

Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong Stock Exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 168 Dongping Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215123
  • China
+86 0512
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Corporate Office
  • Number 168 Dongping Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215123
  • China
+86 0512

Innovent Biologics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innovent Biologics Stock Performance

As of 13-Nov-2026, Innovent Biologics’s stock price is $10.80. Its current market cap is $18.8B with 1.74B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.80 $11.10 $8.87 - $14.38 $18.8B 1.74B 11.7M $0.10

Innovent Biologics Financials Summary

As of 30-Jun-2026, Innovent Biologics has a trailing 12-month revenue of $2.24B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 15,423,145 15,995,610 6,993,816 8,231,917
Revenue 2,244,594 1,813,509 1,313,071 877,198
EBITDA 209,962 122,466 (24,660) (176,371)
Net Income 176,122 113,132 (13,188) (145,291)
Total Assets 6,125,230 5,337,922 2,959,220 2,909,934
Total Debt 341,935 402,443 387,809 510,754
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Innovent Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Innovent Biologics‘s full profile, request access.

Request a free trial

Innovent Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong Stock Exchange in 201
Pharmaceuticals
Suzhou, China
8,754 As of 2026

Shanghai, China
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Innovent Biologics Competitors (42)

One of Innovent Biologics’s 42 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abbisko Medicine Formerly VC-backed Shanghai, China
CStone Pharmaceuticals Formerly VC-backed Suzhou, China
Alphamab Oncology Formerly VC-backed Suzhou, China
BeOne Medicines Formerly PE-Backed Beijing, China
Incyte Formerly VC-backed Wilmington, DE
You’re viewing 5 of 42 competitors. Get the full list »

Innovent Biologics Patents

Innovent Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026233299-A1 Methods of treating subjects having obesity Pending 06-May-2025
WO-2026223801-A1 Modified dsrna and use thereof Pending 25-Apr-2025
WO-2026214626-A1 Antigen-binding protein construct specifically binding to il-4rα and ox40l, and use thereof Pending 09-Apr-2025
WO-2026214624-A1 Method for preventing or treating inflammatory diseases Pending 09-Apr-2025
WO-2026214625-A1 Pharmaceutical composition comprising anti-il-4rα/tslp bispecific antibody and use thereof Pending 09-Apr-2025
To view Innovent Biologics’s complete patent history, request access »

Innovent Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Innovent Biologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Innovent Biologics‘s full profile, request access.

Request a free trial

Innovent Biologics Investments (5)

Innovent Biologics’s most recent deal was a PE Growth/Expansion with IASO Biotechnology. The deal was made on 05-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
IASO Biotechnology 05-Jul-2024 PE Growth/Expansion Drug Discovery
Affini-T 17-Mar-2022 Early Stage VC Drug Discovery
Etana Biotechnologies Indonesia 14-Sep-2021 Later Stage VC Biotechnology
AnHeart Therapeutics 01-Sep-2021 Early Stage VC Biotechnology
Ascentage Pharma 14-Jul-2021 PIPE Drug Discovery
To view Innovent Biologics’s complete investments history, request access »

Innovent Biologics ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Innovent Biologics’s complete esg history, request access »

Innovent Biologics Exits (2)

Innovent Biologics’s most recent exit was on 17-Mar-2022 from Affini-T. The exit was categorized as with 13 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Affini-T 17-Mar-2022 Completed
  • 13 buyers
AnHeart Therapeutics 01-Sep-2021 Early Stage VC Completed
  • 7 buyers
To view Innovent Biologics’s complete exits history, request access »

Innovent Biologics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
InnoPinnacle Shanghai, China 2021

Innovent Biologics FAQs

  • When was Innovent Biologics founded?

    Innovent Biologics was founded in 2011.

  • Where is Innovent Biologics headquartered?

    Innovent Biologics is headquartered in Suzhou, China.

  • What is the size of Innovent Biologics?

    Innovent Biologics has 8,754 total employees.

  • What industry is Innovent Biologics in?

    Innovent Biologics’s primary industry is Pharmaceuticals.

  • Is Innovent Biologics a private or public company?

    Innovent Biologics is a Public company.

  • What is Innovent Biologics’s stock symbol?

    The ticker symbol for Innovent Biologics is 01801.

  • What is the current stock price of Innovent Biologics?

    As of 13-Nov-2026 the stock price of Innovent Biologics is $10.80.

  • What is the current market cap of Innovent Biologics?

    The current market capitalization of Innovent Biologics is $18.8B.

  • What is Innovent Biologics’s current revenue?

    The trailing twelve month revenue for Innovent Biologics is $2.24B.

  • Who are Innovent Biologics’s competitors?

    Abbisko Medicine, CStone Pharmaceuticals, Alphamab Oncology, BeOne Medicines, and Incyte are some of the 42 competitors of Innovent Biologics.

  • What is Innovent Biologics’s annual earnings per share (EPS)?

    Innovent Biologics’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process